Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06586957 · ClinicalTrials.gov registry record · Phase 1
A Study With NKT3964 for Adults With Advanced/Metastatic Solid Tumors
A Phase 1 study of Ovarian Cancer and Solid Tumor, sponsored by NiKang Therapeutics.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 150
- Enrollment target
- 19
- Study locations
NCT06586957: Recruiting Phase 1 study of Ovarian Cancer and Solid Tumor, sponsored by NiKang Therapeutics.
NCT06586957 is a Phase 1 study of Ovarian Cancer and Solid Tumor that is actively recruiting participants, run by NiKang Therapeutics. The registered enrollment target is 150 participants, below the 728-participant average among 322 other Ovarian Cancer trials with a reported enrollment target (79% lower). The trial reports 19 study locations across 13 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06586957, a Phase 1 study of Ovarian Cancer and Solid Tumor, is actively recruiting participants, sponsored by NiKang Therapeutics.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 150 participants
- Enrollment target
- 19
- Study locations
Study Summary
The goal of the Dose Escalation phase of the study is to evaluate the safety, tolerability, pharmacokinetics (PK) and preliminary anti-tumor activity to determine the preliminary recommended dose for expansion (RDE) of NKT3964 in adults with advanced or metastatic solid tumors. The goal of the Expansion phase of the study is to evaluate the preliminary anti-tumor activity of NKT3964 at the RDE based on objective response rate (ORR) and determine the preliminary recommended Phase 2 dose (RP2D).
Primary Outcome
DLTs graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) version 5.0
Conditions Studied
Interventions
- DRUG NKT3964
Study Locations (19)
California
- University of California - Los Angeles - Los Angeles
- UCSF - San Francisco
Florida
- Florida Cancer Specialists & Research Institute - Lake Mary
- AdventHealth Cancer Institute - Orlando
Georgia
- Emory Winship Cancer Institute - Atlanta
- Augusta University - Augusta
Pennsylvania
- Sidney Kimmell Cancer Center - Jefferson Health - Philadelphia
- UPMC - Pittsburgh
Texas
- NEXT Oncology - Austin
- UT Southwestern - Dallas
Virginia
- University of Virginia - Charlottesville
- NEXT Virginia - Fairfax
Arkansas
- University of Arkansas Medical School - Little Rock
Colorado
- SCRI at HealthOne - Denver
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 150 participants |
| Start Date | 2024-09-19 |
| Est. Completion | 2029-05 |
| Phase | Phase 1 |
What NCT06586957 shows while recruiting
NCT06586957 is an interventional study that assigns participants to a tested intervention. The registered 150 participants enrollment target is mid-sized for trials with a published cap, below the 728-participant average among 322 other Ovarian Cancer trials with a reported enrollment target (79% lower).
The record links to 10 conditions, with Ovarian Cancer appearing as the primary indexed condition, and to 1 intervention - of which NKT3964 is the first listed.
NCT06586957 lists 19 locations in 13 states (California, Florida, Georgia).
Frequently Asked Questions
What is clinical trial NCT06586957 about?
NCT06586957 is a clinical study titled "A Study With NKT3964 for Adults With Advanced/Metastatic Solid Tumors". The goal of the Dose Escalation phase of the study is to evaluate the safety, tolerability, pharmacokinetics (PK) and preliminary anti-tumor activity to determine the preliminary recommended dose for expansion (RDE) of NKT3964 in adults with advanced or metastatic solid tumors. The goal of the Expan...
What is the current status of trial NCT06586957?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 150 participants. The study started on 2024-09-19. Estimated completion is 2029-05.
What conditions does trial NCT06586957 study?
This clinical trial studies the following conditions: Ovarian Cancer, Solid Tumor, Advanced Solid Tumor, Solid Tumor, Adult, Ovarian Neoplasms.
What interventions are being tested in trial NCT06586957?
The interventions under investigation include: NKT3964 (DRUG).
Who is sponsoring clinical trial NCT06586957?
This trial is sponsored by NiKang Therapeutics, which has 5 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06586957 being conducted?
This trial has 19 study locations across Arkansas, California, Colorado, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Ovarian Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06586957's enrollment target sits among peer trials
150 120th of 322 higher than 200 of 322 other Ovarian Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Ovarian Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Phase I/IIa Study of AZD5335 as Monotherapy and Combination Therapy in Participants With Solid Tumors
RECRUITING · Phase 1
-
A Study to Assess Adverse Events, Change in Disease Activity and How Intravenous (IV) ABBV901 Moves Through the Body Alone or in Combination With Bevacizumab in Adult Participants With Ovarian Cancer
RECRUITING · Phase 1
-
A Phase I/IIa Study of AZD8205 Given Alone or Combined, in Participants With Advanced/Metastatic Solid Malignancies
RECRUITING · Phase 1
-
Study of Orally Administered MOMA-313 in Participants With Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
A Study With NKT5097 for Adults With Advanced/Metastatic Solid Tumors
RECRUITING · Phase 1
-
A Study of MT-4561 in Patients With Various Advanced Solid Tumors
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00412594 · 150 participants · Phase 2
Cladribine and Rituximab in Treating Patients With Hairy Cell Leukemia
- NCT01484730 · 150 participants
A Pilot Study to Evaluate Multi-Spectral and Laser Speckle Imaging and Multiphoton Microscopy During Vascular Occlusion
- NCT01985919 · 150 participants
Protocol for Facilitating the Acquisition of Research Bone Marrow and Blood Samples
- NCT02016248 · 150 participants · NA
SBRT Boost for Unfavorable Prostate Cancer'
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI